EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Combined PARP14 inhibition and PD-1 blockade promotes cytotoxic T cell quiescence and modulates macrophage polarization in relapsed melanoma

Rotem Leshem iD, Kieran Neil Sefton iD, Chun Wai Wong iD, I-Hsuan Lin iD, Dervla Tamara Isaac iD, Mario Niepel iD, Adam Hurlstone iD

Journal for ImmunoTherapy of Cancer · 2025

DOI: 10.1136/jitc-2024-010683 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2025. Verfasst von Rotem Leshem und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infection, Immunity and Respiratory Medicine, The University of Manchester, Manchester, UK. Hauptthemen laut MEDLINE: Melanoma, Programmed Cell Death 1 Receptor, Poly(ADP-ribose) Polymerases, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ribon Therapeutics, Worldwide Cancer Research, Melanoma Research Alliance.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Programmed cell death 1 (PD-1) signaling blockade by immune checkpoint inhibitors (ICI) effectively restores immune surveillance to treat melanoma. However, chronic interferon-gamma (IFNγ)-induced immune homeostatic responses in melanoma cells contribute to immune evasion and acquired resistance to ICI. Poly ADP ribosyl polymerase 14 (PARP14), an IFNγ-responsive gene product, partially mediates IFNγ-driven resistance. PARP14 inhibition prolongs PD-1 blockade responses in preclinical models, but fails to achieve full tumor clearance, suggesting the involvement of additional resistance mechanisms.

Methods

We identified a robust PARP14 catalytic inhibitor gene signature and evaluated its association with patient survival. Using preclinical models and single-cell RNA sequencing, we investigated immune and tumor cell adaptations to PARP14 inhibition combined with PD-1 blockade.

Results

Combining PARP14 inhibition and PD-1 blockade suppressed tumor-associated macrophages while increasing proinflammatory memory macrophages. Moreover, this combination mitigated the terminal exhaustion of cytotoxic T cells by inducing a quiescent state, thereby preserving functionality. Despite the enhanced immune responses, tumor cells developed adaptive resistance by engaging alternative immune evasion pathways.

Conclusions

Although adaptive resistance mechanisms re-emerge, PARP14 inhibition combined with PD-1 blockade offers a promising strategy to enhance treatment outcomes and overcome ICI resistance in melanoma, as immune cells are primed for further therapeutic interventions that leverage the quiescent state.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaProgrammed Cell Death 1 ReceptorPoly(ADP-ribose) PolymerasesImmune Checkpoint InhibitorsT-Lymphocytes, CytotoxicPoly(ADP-ribose) Polymerase InhibitorsMacrophagesHumansAnimalsMiceCell Line, Tumor

Stichwörter der Autor:innen

Immune Checkpoint InhibitorMacrophageRelapseSkin CancerT cell

Substanzen

Programmed Cell Death 1 ReceptorPoly(ADP-ribose) PolymerasesImmune Checkpoint InhibitorsPARP14 protein, humanPoly(ADP-ribose) Polymerase InhibitorsPDCD1 protein, human

Autor:innen und Institutionen

  • Division of Infection, Immunity and Respiratory Medicine, The University of Manchester, Manchester, UK.
  • Lydia Becker Institute of Immunology and Inflammation, The University of Manchester, Manchester, UK.
  • School of Biological Sciences, The University of Manchester, Manchester, UK.
  • Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
  • Bioinformatics Core Facility, The University of Manchester, Manchester, UK.

ORCID-Profile: Rotem Leshem, Kieran Neil Sefton, Chun Wai Wong, I-Hsuan Lin, Dervla Tamara Isaac, Mario Niepel, Adam Hurlstone

Förderung

  • Ribon Therapeutics
  • Worldwide Cancer Research
  • Melanoma Research Alliance
  • Hong Kong Scholarship for Excellence Scheme

Zitieren

APA

Leshem, R., Sefton, K. N., Wong, C. W., Lin, I. H., Isaac, D. T., Niepel, M., & Hurlstone, A. (2025). Combined PARP14 inhibition and PD-1 blockade promotes cytotoxic T cell quiescence and modulates macrophage polarization in relapsed melanoma. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-010683

Vancouver

Leshem R, Sefton KN, Wong CW, Lin IH, Isaac DT, Niepel M, et al. Combined PARP14 inhibition and PD-1 blockade promotes cytotoxic T cell quiescence and modulates macrophage polarization in relapsed melanoma. Journal for ImmunoTherapy of Cancer. 2025. doi:10.1136/jitc-2024-010683

BibTeX
@article{Leshem2025,
  author = {Leshem, Rotem and Sefton, Kieran Neil and Wong, Chun Wai and Lin, I-Hsuan and Isaac, Dervla Tamara and Niepel, Mario and Hurlstone, Adam},
  title = {Combined PARP14 inhibition and PD-1 blockade promotes cytotoxic T cell quiescence and modulates macrophage polarization in relapsed melanoma},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  doi = {10.1136/jitc-2024-010683}
}
Kostenlos starten →